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Abstract 
Review on Myelodysplastic/myeloproliferative 
neoplasm with ring sideroblasts and thrombocytosis 
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Clinics and pathology 
Disease 
Myelodysplastic/myeloproliferative neoplasm with 
ring sideroblasts and thrombocytosis (MDS/MPN-
RS-T), formerly a provisional diagnosis of refractory 
anemia with ring sideroblasts associated with 
marked thrombocytosis (RARS-T) under the 
MDS/MPN unclassifiable group, has been 
recognized as a full entity in the 2016 WHO 
classification (Arber et al., 2016). It is characterized 
by thrombocytosis of ≥450 x 109/L, refractory 
anemia, dyserythropoiesis with excess ring 
sideroblasts (≥15% of erythroid precursors, 
irrespective of SF3B1 mutational status), and 
megakaryocytes morphologically resembling that 
which may be seen in primary myelofibrosis (PMF) 
or essential thrombocythemia (ET). 
Phenotype/cell stem origin 
The etiopathogenesis of MDS/MPN-RS-T is 
heterogeneous (Gurevich et al., 2011). Ring  
sideroblasts be a manifestation of abnormal 
erythropoiesis with mitochondrial iron overload 
(Patnaik et al., 2015). 
Epidemiology 
MDS/MPN-RS-T is a rare disorder accounting for 
<1% of all cases of MDS (Orazi et al. 2008).  
In one study of 18 patients, M:F ratio was 1.25:1 and 
age range was 40-83 years with a median of 66 years 
(Gurevich et al., 2011). 
Clinics 
The Gurevich et al. study also found presenting signs 
and symptoms of fatigue (5/18), "heavy"/abnormal 
menstrual bleeding (2/18), nosebleed (2/18), upper 
respiratory tract infection/flu-like symptoms (2/18), 
weight loss (1/18), and chest pain (1/18). 5/18 
patients reported no significant symptoms and 
presented with incidental anemia and/or 
thrombocytopenia. Splenomegaly was palpable in 
2/18 patients; the remainder of the patients (16/18) 
had an unremarkable physical examination.  
Platelet count ranged from 515-1100 x 109/L with a 
median of 645 x 109/L. Hemoglobin ranged from 
7.2-12.6 g/dL with a median of 10.2 g/dL. Leukocyte 
count was normal in 14/18 patients and slightly 
below reference range in 1/18 patients.  
The remaining 3/18 patients showed a mildly 
elevated leukocyte count that ranged from 12.9-16.3 
x 109/L (Gurevich et al., 2011). 
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Figure:  Image showing a peripheral blood smear in the left panel with thrombocytosis. A bone marrow biopsy is shown on the 
right with an atypical megakaryocyte and numerous ring sideroblasts (right inset). 
 
Pathology 
Peripheral blood findings include thrombocytosis 
with megathrombocytes, macrocytic or normocytic 
normochromic anemia with anisopoikilocytosis, and 
myeloid left shift with mild dysplastic features. Bone 
marrow aspirate smear findings include increased 
megakaryocytes, myeloid left shift with mild 
dysplastic features (including hypogranulation and 
abnormal nuclear lobation) and <5% blasts, relative 
erythroid preponderance with dysplastic features 
(including nuclear-cytoplasmic dyssynchrony, 
megaloblastic changes, binucleated erythroids, 
karyorrhexis, and nuclear budding) and increased 
ring sideroblasts (≥15%).  
Bone marrow core biopsy and clot section findings 
include a hypercellular marrow with megakaryocyte 
hyperplasia and increased clustering with dysplastic 
cytomorphology (including abnormally large, 
hyperchromatic, hypolobated, and 
micromegakaryocytic forms) (Gurevich et al., 2011). 
Treatment 
Management is typically individualized to address 
the anemia (erythropoiesis stimulating agents and/or 
transfusion) and the thrombotic risk (aspirin).  
The value of cytoreductive therapy (hydroxyurea, 
lenalidomide, IFN-?, busulfan, anagrelide) is 
uncertain and may exacerbate the baseline anemia. 
Prognosis 
Using either the IPSS for MDS or the revised IPSS,  
 
 
most patients with MDS/MPN-RS-T fall into a low 
risk group.  
Overall prognosis is intermediate between that of ET 
and myelodysplastic syndrome with ring 
sideroblasts (MDS-RS) (Patnaik et al. 2015). 
Compared to patients with ET, patients with 
MDS/MPN-RS-T have been found to have a shorter 
overall and leukemia-free survival but a lower risk 
of thrombosis. Compared to patients with MDS-RS, 
patients with MDS/MPN-RS-T have been found to 
have better survival but a higher risk of thrombosis 
(Broseus et al., 2012). 
Genetics 
Note 
Somatic mutations in several genes are seen in 
MDS/MPN-RS-T. Notably mutations in JAK2 are 
frequent, seen in 30-70% of cases.   
Most cases harbor a specific JAK2 point mutation: 
JAK2V617F.  
Mutations in SF3B1 are also common (70-95% of 
cases) and associated with the morphologic finding 
of ring sideroblasts.  
MPL and CALR mutations are rare (<5% of cases). 
Cytogenetics 
Cytogenetics morphological 
No clonal cytogenetic abnormality is detected in 
about 80% of patients (Patnaik et al., 2015). 
Recurrent cytogenetic abnormalities have not been 
described to date. 
Genes involved and 
proteins 
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MPL (MPL proto-oncogene, 
thrombopoietin receptor) 
Location 1p34.2 
Protein 
MPL encodes for CD110, also known as 
thrombopoietin receptor, which plays a critical role 
in thrombopoiesis. Thrombopoietin ( THPO)-
CD110 binding leads to receptor dimerization and 
downstream signaling. Mutations leading to 
constitutive activation of CD110 have been linked to 
overproduction of abnormal megakaryocytes 
(Tefferi et al., 2014). 
SF3B1 (splicing factor 3b subunit 1) 
Location 2q33.1 
Protein 
SF3B1 encodes for subunit one of the splicing factor 
3b protein complex. Splicing factor 3b, splicing 
factor 3a, and a 12S RNA unit combine to form the 
U2 small nuclear riboproteins complex (U2 snRNP). 
The splicing factor 3a/3b complex may function as 
an anchor region for U2 snRNP to bind pre-mRNA. 
JAK2 (janus kinase 2) 
Location 9p24.1 
Protein 
JAK2 encodes for the predominant kinase of 
erythropoietin receptor signaling. JAK2V617F 
mutations lead to constitutive activation of and 
downstream signalling by this kinase, which allows 
hematopoietic cells to grow in a cytokine-
independent manner. 
CALR (calreticulin) 
Location 19p13.13 
Protein 
CALR encodes for calreticulin, which has many 
functions including calcium homeostasis, protein 
folding, cell proliferation, and apoptosis. CALR 
mutations may be found in patients with JAK2-
negative/MPL-negative ET and PMF. 
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